Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma
Blood · 25.09.2025 · 146 (13) · 1575-1585
DOI: 10.1182/blood.2024028107 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, erschienen am 25.09.2025. Verfasst von Benjamin Diamond und 28 weiteren Autor:innen. Beteiligte Einrichtung: Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL. Hauptthemen laut MEDLINE: Multiple Myeloma, ADP-ribosyl Cyclase 1, Drug Resistance, Neoplasm, Antibodies, Monoclonal. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Monoclonal antibodies targeting CD38 are a therapeutic mainstay in multiple myeloma (MM). Although they have contributed to improved outcomes, most patients still experience disease relapse, and little is known about tumor-intrinsic mechanisms of resistance to these drugs. Antigen escape has been implicated as a mechanism of tumor-cell evasion in immunotherapy. Yet, it is unknown whether MM cells can develop permanent resistance to anti-CD38 antibodies by acquiring genomic events leading to biallelic disruption of the CD38 gene locus. Here, we analyzed whole-genome and whole-exome sequencing data from patients 701 newly diagnosed MM, 67 patients at relapse with naivety to anti-CD38 antibodies, and 50 patients collected at relapse after anti-CD38 antibodies. We report a loss of CD38 in 10 of 50 patients (20%) after CD38 therapy, 3 of whom exhibited a loss of both copies. Two of these cases showed convergent evolution in which distinct subclones independently acquired similar advantageous variants. Functional studies on missense mutations involved in biallelic CD38 events revealed that 2 variants, L153H and C275Y, decreased binding affinity and antibody-dependent cellular cytotoxicity of the commercial antibodies daratumumab and isatuximab. However, a third mutation, R140G, conferred selective resistance to daratumumab, while retaining sensitivity to isatuximab. Clinically, patients with MM are often rechallenged with CD38 antibodies after disease progression and these data suggest that next-generation sequencing may play a role in subsequent treatment selection for a subset of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
- Department of Oncology, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada.
- Heidelberg Myeloma Center, Department of Internal Medicine V, Medical Faculty, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
- Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg University, and German Cancer Research Center, Heidelberg, Germany.
- Department of Medicine, Mayo Clinic, Phoenix, AZ.
ORCID-Profile: Benjamin Diamond, Michael Durante, Alexey Rak, Damian J Green, Esteban Braggio, Shaji Kumar, Marc S Raab, Francesco Maura
Förderung
- NCI NIH HHS
Zitieren
APA
Diamond, B., Baughn, L., Poorebrahim, M., Poos, A. M., Lee, H., Kaddoura, M., Wiedmeier-Nutor, J. E., Durante, M., Otteson, G., Jevremovic, D., Tang, H., Fröhling, S., Baertsch, M. A., Papadimitriou, M., Ziccheddu, B., Jelinek, T., Lemoine, C., Rak, A., Green, D. J., …, & Maura, F. (2025). Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma. Blood, 146(13), 1575-1585. https://doi.org/10.1182/blood.2024028107
Vancouver
Diamond B, Baughn L, Poorebrahim M, Poos AM, Lee H, Kaddoura M, et al. Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma. Blood. 2025;146(13):1575-1585. doi:10.1182/blood.2024028107
BibTeX
@article{Diamond2025,
author = {Diamond, Benjamin and Baughn, Linda and Poorebrahim, Mansour and Poos, Alexandra M and Lee, Holly and Kaddoura, Marcella and Wiedmeier-Nutor, J Erin and Durante, Michael and Otteson, Gregory and Jevremovic, Dragan and Tang, Hongwei and Fröhling, Stefan and Baertsch, Marc A and Papadimitriou, Marios and Ziccheddu, Bachisio and Jelinek, Tomas and Lemoine, Cendrine and Rak, Alexey and Green, Damian J and Landgren, Ola and Neri, Paola and Bergsagel, Leif and Braggio, Esteban and Kumar, Shaji and Raab, Marc S and Fonseca, Rafael and Bahlis, Nizar and Weinhold, Niels and Maura, Francesco},
title = {Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma},
journal = {Blood},
year = {2025},
volume = {146},
number = {13},
pages = {1575--1585},
doi = {10.1182/blood.2024028107}
}
EUVIMED